News for AUPH Stock

Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024 Aurinia to Participate in Jefferies London Healthcare Conference Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024 Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024 Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference Aurinia Announces Board Restructuring Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference Aurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024 ILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders’ Voices Expressed at the AGM Aurinia to Participate in Upcoming Investor Healthcare Conferences Aurinia Announces 2024 Annual General Meeting Results Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024 Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce Aurinia Provides Update on Proxy Statement Aurinia Pharmaceuticals Shareholder Urges Fellow Shareholders to Withhold Support for CEO Peter Greenleaf Aurinia Will Attend 2024 Jefferies Global Healthcare Conference Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024 Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024 Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder Value Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024 Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program Aurinia to Participate in Upcoming Investor Healthcare Conferences Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024 Life Sciences Ontario Announces Recipients of 2024 LSO Awards Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results Aurinia Submits IND Application to US Food & Drug Administration for AUR 200 Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023 Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023 Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023 Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR) Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023 Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events MKT Capital Pleased with Aurinia’s Commencement of a Strategic Review Process Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy MKT Capital Calls on Aurinia’s Board of Directors to Respect the Message Sent by Shareholders at 2023 Annual Meeting LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees MKT Capital Thanks Fellow Shareholders for Their Strong Support at Aurinia’s 2023 Annual Meeting Aurinia Announces 2023 Annual General Meeting Results MKT Capital Comments on Aurinia’s Largest Shareholder’s Plans to WITHHOLD Support for the Majority of the Board at the 2023 Annual Meeting Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference MKT Capital Issues Statement Regarding Aurinia’s Disappointing First Quarter 2023 Financial Results Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin) Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys MKT Capital Issues Letter to Aurinia Shareholders Announcing its Intention to Withhold Support for Three Directors at 2023 Annual Meeting Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023 Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023 Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aurinia Announces PTAB Has Terminated Inter Partes Review Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022 Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022 Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022 Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022 Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress Aurinia Reports First Quarter 2022 Financial and Operational Results Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022 Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022 Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2021 Financial Results on February 28, 2021 Aurinia Pharmaceuticals to Present at the 11th Annual Leerink Global Healthcare Conference Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN) Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021 Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021 Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotech Conference Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights Aurinia Pharmaceuticals to Release Second Quarter 2021 Financial Results on August 5, 2021 Aurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange Aurinia Awards $250,000 in Grants to Support Patient Navigation Programs Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA) Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors Aurinia Announces Results of the 2021 Annual General Meeting Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021 Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence Report Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights Aurinia Pharmaceuticals to Present at the SVB Leerink 10th Annual Global Healthcare Conference Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021 FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis Aurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare Conferences Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan Aurinia Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Aurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19 Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020 Aurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.com Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome